Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00371423 | Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions | PHASE3 | COMPLETED | 247 | — | — | Mar 1, 2005 | Sep 1, 2010 | Feb 2, 2012 | 25 | United States, New Zealand +2 |
| NCT00371475 | A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions | PHASE3 | COMPLETED | 150 | — | — | Mar 1, 2005 | May 1, 2011 | Feb 2, 2012 | 25 | United States, New Zealand +1 |
| NCT00371748 | A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels | PHASE3 | COMPLETED | 261 | — | — | Feb 1, 2005 | Apr 1, 2011 | Feb 2, 2012 | 25 | United States, New Zealand +1 |
| NCT00371709 | TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions | PHASE3 | COMPLETED | 871 | — | — | Aug 1, 2004 | Mar 1, 2010 | Feb 2, 2012 | 62 | United States, Australia +5 |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | OTHER | Control data derived from ATLAS Workhorse Trial |
| Arm 3 | OTHER | Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS |
| Name | Type | Description |
|---|---|---|
| TAXUS Liberté™-SR | DEVICE | Paclitaxel-Eluting Coronary Stent System |
| TAXUS Liberté-SR | DEVICE | Paclitaxel-Eluting Coronary 38 mm Stent |
| TAXUS™ Express | DEVICE | Paclitaxel-Eluting Coronary Stent System |
| TAXUS™ Express2 | DEVICE | Paclitaxel-Eluting Coronary Stent System |
| Express2 | DEVICE | Coronary Stent System |
General Inclusion Criteria: 1. Patient is ≥18 years old. 2. Eligible for percutaneous coronary intervention (PCI) 3. Documented stable angina pectoris or unstable angina pectoris with documented ischemia, or documented silent ischemia 4. Left ventricular ejection fraction (LVEF) of ≥25% 5. Acceptab...